Beyond Palliation: Exploring Transplantation Options for Fontan Patients

The Ahmanson/UCLA Congenital Heart Disease Center Presents its Fontan symposium providing a comprehensive update on the long-term issues faced by adult Fontan survivors. The course focuses on patients with “failing” Fontan physiology and the available tools and therapies for the treatment of this challenging subset of patients, including updates on medical therapies, catheter-based and surgical techniques for palliation and support. The ultimate therapeutic options of orthotopic heart and multi-organ transplantation are covered in detail as the need grows in this aging Fontan population.

Target Audience

Adult and Pediatric Congenital Cardiologists, Congenital and Transplant Cardiac Surgeons, Heart Failure/Transplant Specialists, Hepatologists, Liver Transplant Surgeons, Cardiac Intensivists, Cardiology and Cardiac Surgery Trainees, Cardiac Nurses, Nurse Practitioners and Physician Assistants.
 

REGISTRATION INFORMATION

Course Fee

• $150 Physicians
• $95 Nurses and Allied Health Professionals
• $20 Fellows/Residents

Refunds

Cancellations must be received by email to ccpd@mednet.ucla.edu by Friday, February 2, 2024, and are subject to a $25 processing fee. No refunds will be granted after that date. If, for any reason, the course must be canceled, discontinued, or rescheduled, a full refund will be provided.

Questions

If you have questions about enrollment, please email ccpd@mednet.ucla.edu or call (310) 794-2620.

EXHIBITOR INFORMATION

Please email ccpdSEG@mednet.ucla.edu.

OBJECTIVES

At the conclusion of this course, participants should be able to:

• Define the “failing” Fontan patient
• Utilize evidence-based medical therapies for treatment and surveillance of the Fontan survivor
• Diagnose Fontan associated liver disease
• Refer appropriate Fontan patients for catheter-based mechanical and electrical interventions
• Identify the role and the limitations of Fontan conversion surgery
• Identify Fontan patients that may benefit from transplantation or mechanical support
• Describe the short- and intermediate-term outcomes of single and multi-organ transplantation in Fontan patients

ACCREDITATION

The David Geffen School of Medicine at UCLA is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The David Geffen School of Medicine at UCLA, designates this live activity for a maximum of 7.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Registered Nurses
The California State Board of Registered Nursing accepts courses approved for the AMA PRA Category 1 Credits™ as meeting the continuing education requirements for license renewal. Nurses from states other than California should inquire with their local State Board for specific continuing education policies.

DISCLOSURES

The FDA has issued a concept paper that classifies commercial support of scientific and educational programs as promotional unless it can be affirmed that the program is “truly independent” and free of commercial influence. In addition to independence, the FDA requires that non-promotional, commercially supported education be objective, balanced and scientifically rigorous. The policy further states that all potential conflicts of interest of the CME staff and faculty be fully disclosed to the program’s participants. In addition, Accreditation Council for Continuing Medical Education policy mandates that the provider adequately manage all identified potential conflicts of interest prior to the program. UCLA fully endorses the letter and spirit of these concepts.